Kevin Dehart, DO
Dermatology · Suffolk, VANPI 1528256872
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Johnson & Johnson at 32.1% of the total. Among dermatology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 658 payments — averaging $38.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$8K
- AbbVie$4K
- LNHC, Inc$3K
- Galderma Laboratories, L.p.$2K
- Sanofi$896
- Novartis$843
- plus $7K from 28 others
What the payments were for
- Consulting fees$7,95031%
- Speaking & faculty fees$3,97316%
- Travel & lodging$1,0054%
- Food & beverage$12,14747%
- Education$5282%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 52 | $8,209 |
| AbbVie | 157 | $3,624 |
| LNHC, Inc | 4 | $2,884 |
| Galderma Laboratories, L.p. | 21 | $2,302 |
| Sanofi | 33 | $896 |
| Novartis | 38 | $843 |
| LEO Pharma Inc. | 40 | $840 |
| UCB, Inc. | 51 | $757 |
| Sun Pharmaceutical Industries Inc. | 41 | $730 |
| Pfizer | 41 | $653 |
| Amgen | 21 | $560 |
| Arcutis Biotherapeutics, Inc. | 27 | $483 |
| Regeneron Healthcare Solutions, Inc. | 22 | $480 |
| Lilly USA, LLC | 25 | $397 |
| VYNE Pharmaceuticals Inc. | 20 | $333 |
| E.r. Squibb & Sons, L.L.C. | 13 | $309 |
| Biofrontera Inc. | 10 | $285 |
| Incyte Corporation | 8 | $149 |
| EPI Health, LLC | 3 | $148 |
| Botanix SB Inc | 1 | $145 |
| Dermavant Sciences, Inc. | 5 | $103 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $102 |
| Genentech USA, Inc. | 3 | $59 |
| Aclaris Therapeutics, Inc. | 3 | $58 |
| Strata Skin Sciences, Inc. | 3 | $43 |
| Dermira, Inc. | 2 | $36 |
| Organon | 2 | $30 |
| Springworks Therapeutics, Inc. | 1 | $28 |
| Verrica Pharmaceuticals Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $22 |
| DUSA Pharmaceuticals, Inc. | 1 | $21 |
| Convatec Inc. | 1 | $13 |
| Hill Dermaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,602 in reported general payments places this provider in the 90th percentile of 396 dermatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 27 | $278,567 |
| Dupixent PenDupilumab | 23 | $109,583 |
| OtezlaApremilast | 18 | $87,802 |
| OpzeluraRuxolitinib Phosphate | 11 | $22,318 |
| Clobetasol Propionate | 90 | $5,408 |
| Betamethasone Valerate | 130 | $3,793 |
| Ketoconazole | 125 | $3,428 |
| Ammonium Lactate | 112 | $2,125 |
| Triamcinolone Acetonide | 127 | $1,674 |
| Ciclopirox | 31 | $1,569 |
| Metronidazole | 34 | $1,565 |
| Clindamycin Phosphate | 49 | $1,422 |
| Imiquimod | 39 | $1,408 |
| Calcipotriene | 12 | $1,137 |
| Fluorouracil | 17 | $1,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $560 | $87,80218 claims |
| Incyte CorporationOpzelura | $149 | $22,31811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 396 dermatology providers in Virginia.
Other dermatology in Suffolk
- Robert BaerSuffolk$303K
- Naiem IssaVienna$2M
- Saurabh SinghFairfax$1.7M
- Diego DasilvaVirginia Beach$1.1M
- Vishal PatelLeesburg$719K
- Cyndi Torosky TommasoVirginia Beach$717K
- Daniel HurdBlacksburg$545K
- Jonathan SchreiberNorfolk$330K
- David PariserNorfolk$261K
- Hema SundaramFairfax$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.